Indoleamine 2,3-dioxygenase 1 promotes osteosarcoma progression by regulating tumor-derived exosomal miRNA hsa-miR-23a-3p

Background: Osteosarcoma (OS) is the most common primary malignant tumor originating in bone. Immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1) participates in tumor immune tolerance and promotes tumor progression, while the study of IDO1 in OS is limited.Methods: Immunohistochemistry an...

Full description

Saved in:
Bibliographic Details
Main Authors: Dan Yang (Author), Yinxian Chen (Author), Zhen Ning Tony He (Author), Yichen Wang (Author), Chenghui Ke (Author), Yi Luo (Author), Sun Wang (Author), Qichao Ma (Author), Mengjie Chen (Author), Qing Yang (Author), Ziming Zhang (Author)
Format: Book
Published: Frontiers Media S.A., 2023-05-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_a6d2b46d32ec4001ac8b0fe06e5a6b5d
042 |a dc 
100 1 0 |a Dan Yang  |e author 
700 1 0 |a Dan Yang  |e author 
700 1 0 |a Yinxian Chen  |e author 
700 1 0 |a Zhen Ning Tony He  |e author 
700 1 0 |a Yichen Wang  |e author 
700 1 0 |a Chenghui Ke  |e author 
700 1 0 |a Yi Luo  |e author 
700 1 0 |a Sun Wang  |e author 
700 1 0 |a Qichao Ma  |e author 
700 1 0 |a Mengjie Chen  |e author 
700 1 0 |a Qing Yang  |e author 
700 1 0 |a Ziming Zhang  |e author 
245 0 0 |a Indoleamine 2,3-dioxygenase 1 promotes osteosarcoma progression by regulating tumor-derived exosomal miRNA hsa-miR-23a-3p 
260 |b Frontiers Media S.A.,   |c 2023-05-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2023.1194094 
520 |a Background: Osteosarcoma (OS) is the most common primary malignant tumor originating in bone. Immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1) participates in tumor immune tolerance and promotes tumor progression, while the study of IDO1 in OS is limited.Methods: Immunohistochemistry analysis was performed to test the expression of IDO1 and Ki67. The relationship between IDO1 or Ki67 positive count and clinical stage of the patient was analyzed. Laboratory test indexes including serum alkaline phosphatase (ALP), lactate dehydrogenase (LDH), white blood cell (WBC) count and C-reactive protein (CRP) at diagnosis of OS patients were collected. The relationship between positive count of IDO1 and Ki67 or laboratory test indexes was analyzed by Pearson's correlation analysis. IDO1 stably overexpressed cell lines of these cells (MG63 OE, 143B OE and hFOB1.19 OE) were constructed and validated by Western blot and Elisa. Exosomes were isolated from conditioned culture media of these cells and were identified by Zetaview nanoparticle tracking analyzer. Next-generation sequencing was conducted to identify miRNAs enriched in exosomes. Differentially expressed miRNAs (DE miRNAs) were verified in clinical samples and cell lines by qPCR. Biological processes and cell components analysis of DE miRNAs was conducted by GO enrichment analysis using the protein interaction network database.Results: Immunosuppressive enzyme IDO1 was highly expressed in tumor tissues. 66.7% (6/9) of the tissues showed moderately or strongly positive immunostaining signal of IDO1, and 33.3% (3/9) were weakly positive. The expression of IDO1 was positively related to Ki67 and associated with prognostic-related clinical features of OS patients. Overexpression of IDO1 significantly affected the exosome-derived miRNA subsets from MG63, 143B and hFOB1.19 cells. A total of 1244 DE miRNAs were identified, and hsa-miR-23a-3p was further screened as key DE miRNA involved in the progression of OS. GO analysis of target genes of the DE miRNA results showed that target enrichment in the functions of immune regulation and tumor progression.Discussion: Our results indicate that IDO1 has the potential to promote the progression of OS that is related to miRNAs mediated tumor immunity. Targeting IDO1-mediated hsa-miR-23a-3p may be a potential therapeutic strategy for OS treatment. 
546 |a EN 
690 |a osteosarcoma 
690 |a indoleamine 2,3-dioxygenase 1 
690 |a exosome miRNAs 
690 |a tumor immunity 
690 |a immunotherapeutic target 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 14 (2023) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fphar.2023.1194094/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/a6d2b46d32ec4001ac8b0fe06e5a6b5d  |z Connect to this object online.